Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated with Reduced Efficacy of Radiotherapy

Research output: Contribution to journalArticle

Abstract

Radiotherapy is cytotoxic to tumor cells and is therefore a critical component of therapy for many malignancies, including glioblastoma (GBM). We now appreciate the value of the immunomodulatory effects of radiation that may be important to overall therapeutic success in some patients with this primary brain tumor. Although potentially beneficial immune-stimulating properties of radiotherapy treatment have been the focus of recent study, this modality is actually at the same time associated with the depletion of lymphocytes, which are crucial to the defense against neoplastic development and progression. In this review, we describe the association of systemic lymphopenia with poor tumor outcome, present evidence that radiotherapy is an important contributing cause of lymphodepletion, describe the systemic immune context of tumor and brain injury that contributes to immunosuppression, describe other contributing factors to lymphopenia including concomitant medications and treatments, and speculate about the role of the normal physiologic response to brain injury in the immunosuppressive dynamics of GBM. Radiotherapy is one significant and potentially actionable iatrogenic suppressor of immune response that may be limiting the success of therapy in GBM and other tumor types. Altered strategies for radiotherapy more permissive of a vigorous antineoplastic immune response may improve outcome for malignancy.

Original languageEnglish (US)
Pages (from-to)441-453
Number of pages13
JournalClinical Neurosurgery
Volume85
Issue number4
DOIs
StatePublished - Oct 1 2019

Fingerprint

Lymphopenia
Glioblastoma
Radiotherapy
Neoplasms
Brain Injuries
Lymphocyte Depletion
Therapeutics
Radiation Effects
Immunosuppressive Agents
Brain Neoplasms
Antineoplastic Agents
Immunosuppression

Keywords

  • CD4 T cells
  • Glioblastoma
  • Immunity
  • Lymphopenia
  • Neoplasm
  • Radiotherapy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

@article{6148815cbfb44e7aa1d0b42292bd22fa,
title = "Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma: A Potentially Actionable Toxicity Associated with Reduced Efficacy of Radiotherapy",
abstract = "Radiotherapy is cytotoxic to tumor cells and is therefore a critical component of therapy for many malignancies, including glioblastoma (GBM). We now appreciate the value of the immunomodulatory effects of radiation that may be important to overall therapeutic success in some patients with this primary brain tumor. Although potentially beneficial immune-stimulating properties of radiotherapy treatment have been the focus of recent study, this modality is actually at the same time associated with the depletion of lymphocytes, which are crucial to the defense against neoplastic development and progression. In this review, we describe the association of systemic lymphopenia with poor tumor outcome, present evidence that radiotherapy is an important contributing cause of lymphodepletion, describe the systemic immune context of tumor and brain injury that contributes to immunosuppression, describe other contributing factors to lymphopenia including concomitant medications and treatments, and speculate about the role of the normal physiologic response to brain injury in the immunosuppressive dynamics of GBM. Radiotherapy is one significant and potentially actionable iatrogenic suppressor of immune response that may be limiting the success of therapy in GBM and other tumor types. Altered strategies for radiotherapy more permissive of a vigorous antineoplastic immune response may improve outcome for malignancy.",
keywords = "CD4 T cells, Glioblastoma, Immunity, Lymphopenia, Neoplasm, Radiotherapy",
author = "Lawrence Kleinberg and Lindsey Sloan and Stuart Grossman and Michael Lim",
year = "2019",
month = "10",
day = "1",
doi = "10.1093/neuros/nyz198",
language = "English (US)",
volume = "85",
pages = "441--453",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Radiotherapy, Lymphopenia, and Host Immune Capacity in Glioblastoma

T2 - A Potentially Actionable Toxicity Associated with Reduced Efficacy of Radiotherapy

AU - Kleinberg, Lawrence

AU - Sloan, Lindsey

AU - Grossman, Stuart

AU - Lim, Michael

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Radiotherapy is cytotoxic to tumor cells and is therefore a critical component of therapy for many malignancies, including glioblastoma (GBM). We now appreciate the value of the immunomodulatory effects of radiation that may be important to overall therapeutic success in some patients with this primary brain tumor. Although potentially beneficial immune-stimulating properties of radiotherapy treatment have been the focus of recent study, this modality is actually at the same time associated with the depletion of lymphocytes, which are crucial to the defense against neoplastic development and progression. In this review, we describe the association of systemic lymphopenia with poor tumor outcome, present evidence that radiotherapy is an important contributing cause of lymphodepletion, describe the systemic immune context of tumor and brain injury that contributes to immunosuppression, describe other contributing factors to lymphopenia including concomitant medications and treatments, and speculate about the role of the normal physiologic response to brain injury in the immunosuppressive dynamics of GBM. Radiotherapy is one significant and potentially actionable iatrogenic suppressor of immune response that may be limiting the success of therapy in GBM and other tumor types. Altered strategies for radiotherapy more permissive of a vigorous antineoplastic immune response may improve outcome for malignancy.

AB - Radiotherapy is cytotoxic to tumor cells and is therefore a critical component of therapy for many malignancies, including glioblastoma (GBM). We now appreciate the value of the immunomodulatory effects of radiation that may be important to overall therapeutic success in some patients with this primary brain tumor. Although potentially beneficial immune-stimulating properties of radiotherapy treatment have been the focus of recent study, this modality is actually at the same time associated with the depletion of lymphocytes, which are crucial to the defense against neoplastic development and progression. In this review, we describe the association of systemic lymphopenia with poor tumor outcome, present evidence that radiotherapy is an important contributing cause of lymphodepletion, describe the systemic immune context of tumor and brain injury that contributes to immunosuppression, describe other contributing factors to lymphopenia including concomitant medications and treatments, and speculate about the role of the normal physiologic response to brain injury in the immunosuppressive dynamics of GBM. Radiotherapy is one significant and potentially actionable iatrogenic suppressor of immune response that may be limiting the success of therapy in GBM and other tumor types. Altered strategies for radiotherapy more permissive of a vigorous antineoplastic immune response may improve outcome for malignancy.

KW - CD4 T cells

KW - Glioblastoma

KW - Immunity

KW - Lymphopenia

KW - Neoplasm

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85073471488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073471488&partnerID=8YFLogxK

U2 - 10.1093/neuros/nyz198

DO - 10.1093/neuros/nyz198

M3 - Article

C2 - 31232425

AN - SCOPUS:85073471488

VL - 85

SP - 441

EP - 453

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -